About Corcept

Corcept Therapeutics Incorporated (NASDAQ: CORT) is a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders. Our lead product candidate, CORLUX, modulates the effect of cortisol -- better known as the “stress hormone” -- by selectively blocking the binding of cortisol to one of its two known receptors, the GR-II receptor (also known as the Type II or GR receptor). Corcept has ongoing Phase 3 studies of CORLUX in two indications – Cushing’s Syndrome and psychotic depression, both unmet medical needs;

• Cushing’s Syndrome: Our Phase 3 clinical program for Cushing’s Syndrome should generate data  in 3Q 2010, which could support an NDA submission by the end of 2010.
• Psychotic Depression: Our Phase 3 clinical program for psychotic depression is actively enrolling patients.
• Next-Generation Selective GR-II Antagonists: Based on positive proof-of-concept data for mitigating antipsychotic-induced weight gain, we  filed our IND for the lead compound in December 2009 and plan to initiate our Phase 1 study in 1Q 2010.  Our plan is to evaluate multiple new indications to establish the broad potential of these selective compounds in regulating cortisol production.

We retain all rights to commercialize CORLUX and our selective GR-II antagonists. Corcept has exclusively licensed from Stanford University the patent for the use of GR-II antagonists to treat the psychotic features of psychotic depression. We own exclusively licensed issued patents and filed patent applications relating to the treatment of multiple disorders also believed to result from, or negatively affected by, prolonged exposure to elevated cortisol (GR-II Antagonist Platform).